Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2017
February 2017, Vol 8, No 1
February 2017, Vol 8, No 1
Increased Utilization of Biosimilars in Oncology Could Save Payers Millions
By
Chase Doyle
Economics & Value
,
Value-Based Care
,
Biosimilars
February 2017, Vol 8, No 1
San Diego, CA—Filgrastim (Neupogen), a short-acting granulocyte colony-stimulating factor (G-CSF), has helped to manage chemotherapy-induced neutropenia in patients with nonmyeloid malignancies, but it comes with a hefty price tag. According to a recent study, biosimilars of filgrastim may provide a more affordable option for US payers, suggested Susan Gabriel, Director of Global Health Economics and Outcomes Research, Teva Pharmaceuticals, Frazer, PA, at the 2016 American Society of Hematology meeting.
Read Article
Value Frameworks Unreliable in Assessing Novel Hematologic Therapies
By
Chase Doyle
Economics & Value
,
Value-Based Care
February 2017, Vol 8, No 1
San Diego, CA—The American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) developed frameworks to determine the relative value of novel therapeutic agents. These value frameworks, however, may need to be modified to assess treatments for hematologic malignancies, suggested Matthew C. Cheung, MD, SM, FRCPC, Clinical Hematologist, Odette Cancer Centre, Toronto, Ontario, Canada, at the 2016 American Society of Hematology meeting.
Read Article
Frontline Use of Bendamustine plus Rituximab Cost-Effective for Indolent B-Cell Non-Hodgkin Lymphoma
By
Chase Doyle
Economics & Value
,
Value-Based Care
February 2017, Vol 8, No 1
San Diego, CA—New research from Canada supports the use of frontline therapy with bendamustine plus rituximab for patients with indolent B-cell non-Hodgkin lymphoma (NHL), reported Andrew Aw, MD, MEng, FRCPC, Division of Hematology, Ottawa Hospital, Ontario, Canada, at the 2016 American Society of Hematology meeting.
Read Article
ASCO Value Framework Ill-Equipped to Assess Value of Therapies in Chronic Lymphocytic Leukemia
By
Chase Doyle
Economics & Value
,
Value-Based Care
,
ASCO’s Value Framework
February 2017, Vol 8, No 1
San Diego, CA—A study examining the feasibility and applicability of the American Society of Clinical Oncology (ASCO) Value Framework in chronic lymphocytic leukemia (CLL) suggests that the tool, although useful in assessing a small percentage of drug regimens, may need to be amended to be useful in CLL, reported Erlene K. Seymour, MD, Assistant Professor, Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, at the 2016 American Society of Hematology meeting.
Read Article
American Society of Hematology 2016: Multiple Myeloma Highlights
Hematologic Malignancies
,
Multiple Myeloma
February 2017, Vol 8, No 1
Read Article
Venetoclax plus Bortezomib and Dexamethasone Produces High Responses in Patients with Relapsed or Refractory Multiple Myeloma
By
Wayne Kuznar
Hematologic Malignancies
,
Multiple Myeloma
February 2017, Vol 8, No 1
San Diego, CA—The addition of venetoclax (Venclexta) to bortezomib (Velcade) and dexamethasone yields high response rates in patients with relapsed or refractory multiple myeloma, especially in patients with disease that is not refractory to bortezomib and who received 1 to 3 previous lines of therapy, according to findings presented by Philippe Moreau, MD, Department of Hematology, Nantes University Hospital, France, at the 2016 American Society of Hematology meeting.
Read Article
Pacritinib Shows Good Efficacy in Myelofibrosis: Will the FDA Release Hold on the Drug?
By
Phoebe Starr
Myelofibrosis
February 2017, Vol 8, No 1
San Diego, CA—The investigational drug pacritinib, a JAK1/JAK2 inhibitor, achieved benefits in patients with myelofibrosis, including a significant reduction in the spleen volume compared with the best available therapy that included the JAK1/JAK2 inhibitor ruxolitinib (Jakafi), according to the phase 3 PERSIST-2 clinical trial. The results were presented by John O. Mascarenhas, MD, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, at the 2016 American Society of Hematology (ASH) meeting.
Read Article
Brentuximab Vedotin Improves Responses Lasting 4 Months in Cutaneous T-Cell Lymphoma
By
Wayne Kuznar
Lymphoma
February 2017, Vol 8, No 1
San Diego, CA—Brentuximab vedotin (Adcetris) monotherapy significantly improved the objective response rate (ORR) lasting ≥4 months compared with the investigator’s choice of standard therapy in patients with cutaneous T-cell lymphoma (CTCL), reported Youn H. Kim, MD, Director, Multidisciplinary Cutaneous Lymphoma Clinic, Stanford University School of Medicine, CA, at the 2016 American Society of Hematology meeting.
Read Article
Chemotherapy-Free Induction with Ibrutinib plus Rituximab Shows Unprecedented Efficacy in MCL
By
Charles Bankhead
Lymphoma
February 2017, Vol 8, No 1
San Diego, CA—Combination induction therapy with ibrutinib (Imbruvica) and rituximab (Rituxan) in patients with mantle-cell lymphoma (MCL) led to objective responses in each of the first 50 patients who received this combination in an ongoing, phase 2 clinical trial presented at the 2016 American Society of Hematology meeting.
Read Article
Pembrolizumab Produces Durable Responses in Relapsed or Refractory Cutaneous T-Cell Lymphoma
By
Wayne Kuznar
Lymphoma
February 2017, Vol 8, No 1
San Diego, CA—The PD-1 inhibitor pembrolizumab (Keytruda) has good activity in patients with relapsed or refractory mycosis fungoides or Sézary syndrome, and the responses it produces are deep and durable, according to study results reported by Michael Khodadoust, MD, PhD, Medicine-Oncology, Division of Oncology, Stanford University School of Medicine, CA, at the 2016 American Society of Hematology meeting.
Read Article
Page 2 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma